KRAS Breakthrough: Karmanos Researchers Redefine What’s Possible in Pancreatic Cancer Treatment
A groundbreaking review led by researchers at the Barbara Ann Karmanos Cancer Institute and Wayne State University—including longtime Sky Foundation collaborator Dr. Asfar Azmi—was recently published in the…
A groundbreaking review led by researchers at the Barbara Ann Karmanos Cancer Institute and Wayne State University—including longtime Sky Foundation collaborator Dr. Asfar Azmi—was recently published in the high-impact Nature journal Signal Transduction and Targeted Therapy (impact factor >50). The article, “Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges,” has already earned international recognition, becoming one of the journal’s most accessed papers, with coverage from OncoDaily News and a high Altmetric score.
KRAS mutations are among the most common and challenging drivers of pancreatic cancer. Once considered “undruggable,” new research is changing that narrative—and Karmanos is helping lead the way. Dr. Azmi’s lab is pioneering next-generation strategies to overcome resistance and improve the effectiveness of KRAS inhibitors, especially in patients with the G12D and G12V mutations prevalent in pancreatic cancer. His team is actively exploring promising combination therapies and leading the charge toward durable, precision-based treatment approaches.
Sky Foundation is proud to have supported early stages of this work through seed funding, and we celebrate this milestone as a shining example of how research and clinical care can work hand-in-hand to bring new hope to patients and families impacted by pancreatic cancer.
Read the full article here.
Sky awards $50,000 grants for the early work national funders will not yet touch.
DonateMore from Sky
KRAS Breakthrough: Karmanos Researchers Redefine What’s Possible in Pancreatic Cancer Treatment
A groundbreaking review led by researchers at the Barbara Ann Karmanos Cancer Institute and Wayne State University—including longtime Sky Foundation collaborator Dr. Asfar Azmi—was recently published in the…
A groundbreaking review led by researchers at the Barbara Ann Karmanos Cancer Institute and Wayne State University—including longtime Sky Foundation collaborator Dr. Asfar Azmi—was recently published in the high-impact Nature journal Signal Transduction and Targeted Therapy (impact factor >50). The article, “Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges,” has already earned international recognition, becoming one of the journal’s most accessed papers, with coverage from OncoDaily News and a high Altmetric score.
KRAS mutations are among the most common and challenging drivers of pancreatic cancer. Once considered “undruggable,” new research is changing that narrative—and Karmanos is helping lead the way. Dr. Azmi’s lab is pioneering next-generation strategies to overcome resistance and improve the effectiveness of KRAS inhibitors, especially in patients with the G12D and G12V mutations prevalent in pancreatic cancer. His team is actively exploring promising combination therapies and leading the charge toward durable, precision-based treatment approaches.
Sky Foundation is proud to have supported early stages of this work through seed funding, and we celebrate this milestone as a shining example of how research and clinical care can work hand-in-hand to bring new hope to patients and families impacted by pancreatic cancer.
Read the full article here.
Sky awards $50,000 grants for the early work national funders will not yet touch.
Donate